Selegiline transdermal system (STS): Assessments of dermal safety in human

Journal of Toxicology - Cutaneous and Ocular Toxicology

Volumn 23, Issue 3, 2004, Pages 179-187

  Pauporte, Michele ^a   Azzaro, Albert J ^b   Moonsammy, George ^b   Maibach, Howard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Somerset Pharmaceuticals   (United States)

Author keywords

Application site reaction; Contact allergenicity; Dermal safety; Selegiline transdermal system

Indexed keywords

PLACEBO; SELEGILINE;

APPLICATION SITE REACTION; ARTICLE; CLINICAL TRIAL; CONTACT ALLERGY; DELAYED HYPERSENSITIVITY; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MACULOPAPULAR RASH; PRURITUS; RASH; SKIN IRRITATION; SKIN TOXICITY; TRANSDERMAL DRUG ADMINISTRATION;

EID: 4944247820     PISSN: 07313829     EISSN: None     Source Type: Journal    
DOI: 10.1081/CUS-200035366     Document Type: Article

References (16)

1. DaPrada M, Zurcher G, Wuthricht I, Haefely W. On tyramine, food, beverages, and the reversible MAO inhibitor moclobemide. J Neural Transm 1988; 26(suppl):31-56.
2. Golbe LI. Deprenyl as symptomatic therapy in parkinson's disease. Clin Neuropharmacol 1988; 11(5):387-400.
3. Heinonen EH, Rinne UK. Selegiline in the treatment of parkinson's disease. Acta Neurol Scand 1989; 126:103-111.
4. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159(11):1869-1875.
5. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64(2):208-214.
6. Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gens Psychiatry 1989; 46(1):45-50.
7. McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EN, Quitkin FM. A placebo-controlled trial of 1-deprenyl in atypical depression. Psychopharmacol Bull 1989; 25(1):63-67.
8. Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN, Mueller EA, Murphy DL. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51(8):607-615.
9. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003; 55(1):27-34.
10. Wecker L, Goodhead ML, Azzaro AJ, Pacheco MA. In The Selegiline Transdermal System (STS): Targeted Effects on Monoamine Oxidases in the Brain, Presented at: American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December 2000.
11. Pauporte M, Maibach HI, Goodhead M, Azzaro AJ, Moonsammy G. Selegiline transdermal system (STS): preclinical assays of dermal safety. J Toxicol Cutaneous Ocular Toxicol 200X; x(x):xx.
12. Data on File. Somerset Pharmaceuticals, Inc.: Tampa, FL.
13. Marzulli F, Maibach HI. Test Methods for Allergic Contact Dermatitis in Humans Dermatotoxicology, 5th ed. Marzulli FN, Maibach HI, eds. New York: Taylor and Frances, 1996; 477-484.
14. Mitchell J, Maibach H. Managing the excited skin syndrome: patch testing hyperirritable skin. Contact Dermatitis 1997; 37(5):193-199.
15. Physicians' Desk Reference. 53rd ed. Montvale, NJ: Thomson Healthcare, 1999; 1535-1538.
16. Patil S, Hogan D, Maibach HI. Transdermal drug delivery systems. In: Marzulli F, Maibach HI, eds. Dermatotoxicology. 5th ed. New York: Taylor and Frances, 1996; 389-396.